Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Stacked from zero: upward is an increase in cash, downward a decrease (in Thousand yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Business revenue consists of income received from analytical services and other sources. The main factors behind the wider loss are the continuation of basic and drug-discovery research, expenses recognized as clinical development progressed in the 3 areas of small-molecule drugs, cancer peptide vaccines and antibody drugs, and the recognition of cost of sales in the cancer precision medicine-related business.
The disclosure includes a description of significant events and other matters related to the going concern assumption. Although circumstances exist that raise significant doubt about the going concern assumption, the company has ¥2,083 million in cash and deposits and has determined that no material uncertainty related to the going concern assumption exists. There are no applicable notes regarding the going concern assumption.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | 335,672 Thousand yen |
| Operating profit | -568,576 Thousand yen |
| Ordinary income | -572,995 Thousand yen |
| Profit attributable to owners of the parent | -574,827 Thousand yen |
| Total assets | 2,338,776 Thousand yen |
| Net assets | 2,062,522 Thousand yen |
| Cash flows from operating activities | -468,733 Thousand yen |
| Cash flows from investing activities | -1,302 Thousand yen |
| Cash flows from financing activities | 463,998 Thousand yen |
| Cash and cash equivalents at end of period | 2,083,300 Thousand yen |
| Segment revenue | Segment Pharmaceutical research and development and related businesses / Net Sales 1,981 Thousand yen / Year on year against the same period last year Not disclosed, Segment Cancer precision medicine-related business / Net Sales 333,691 Thousand yen / Year on year against the same period last year Not disclosed |
| Segment profit | Segment Pharmaceutical research and development and related businesses / Segment profit -319,390 Thousand yen / Year on year against the same period last year Not disclosed, Segment Cancer precision medicine-related business / Segment profit -58,333 Thousand yen / Year on year against the same period last year Not disclosed |
| Impairment loss | 1,302 Thousand yen |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on reversal of stock acquisition rights 550 Thousand yen / Extraordinary loss Impairment loss 1,302 Thousand yen |
| Disclosure regarding the going concern assumption | The disclosure includes a description of significant events and other matters related to the going concern assumption. Although circumstances exist that raise significant doubt about the going concern assumption, the company has ¥2,083 million in cash and deposits and has determined that no material uncertainty related to the going concern assumption exists. There are no applicable notes regarding the going concern assumption. |
| Factors Behind Changes in Business Performance | Business revenue consists of income received from analytical services and other sources. The main factors behind the wider loss are the continuation of basic and drug-discovery research, expenses recognized as clinical development progressed in the 3 areas of small-molecule drugs, cancer peptide vaccines and antibody drugs, and the recognition of cost of sales in the cancer precision medicine-related business. |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Business revenue consists of income received from analytical services and other sources. The main factors behind the wider loss are said to be the continued basic and drug-discovery research on drug candidates, expenses recognized as clinical development progressed in the 3 areas of small-molecule drugs, cancer peptide vaccines and antibody drugs, and the recognition of cost of sales in the cancer precision medicine-related business.